Stryker Corp (NYSE: SYK)

$327.35 ▼ -10.99 (-3.25%)
As of Apr 21, 2026 03:59 PM
Sector: Healthcare Industry: Medical Devices CIK: 0000310764
Market Cap 129.03 Bn
P/E 39.76
P/S 5.14
Div. Yield 0.01
ROIC (Qtr) 0.15
Total Debt (Qtr) 15.86 Bn
Revenue Growth (1y) (Qtr) 11.42
Add ratio to table...

About

Investment thesis

Bull case

  • Stryker’s continued double‑digit organic sales growth, now at 11% for the quarter and projected 8‑9.5% for 2026, reflects a robust pipeline of capital and implant products that are capturing increasing procedural volumes. The company’s Mako robotics platform has already achieved two‑thirds utilization in U.S. knee arthroplasty and one‑third in hip, and the planned introduction of shoulder and spine applications is expected to unlock further market share in high‑margin procedures. As the robotic platform gains broader acceptance, the incremental software licensing and maintenance revenue model will generate predictable, high‑margin recurring cash flows that will offset the initial capital outlay. Additionally, the elevated order book and the recent launch of Triathlon Gold, a dual‑fixation knee implant, provide early evidence that Stryker’s product innovation translates quickly into revenue growth, creating a virtuous cycle of capital deployment and revenue capture.
  • The company’s free‑cash‑flow conversion has risen to 81% of adjusted earnings, indicating strong operational discipline and the capacity to reinvest in both research and development and strategic acquisitions. By maintaining a free‑cash‑flow target of 70‑80% and simultaneously funding a healthy capital expenditure program, Stryker can pursue high‑yield acquisitions—particularly in complementary vascular and health‑IT segments—without compromising its balance sheet. The management’s stated intent to “execute on M&A in 2026” signals a disciplined approach that should generate incremental synergies and cross‑sell opportunities across the medical and orthopedic portfolios.
  • International growth is accelerating, with emerging markets such as South Korea, Japan, Australia, and New Zealand contributing 7.5% to the full‑year organic sales mix. The company’s strategic emphasis on launching products in high‑growth geographies—leveraging the recent favorable regulatory approvals under the EU MDR framework—positions it to capture a larger share of the global orthopedic market before the competition ramps up in those regions. The robust demand in these markets is underpinned by demographic trends, such as aging populations and increased health spending, which are unlikely to reverse in the medium term.
  • Stryker’s gross margin improvement to 65.2%—despite a 10 basis‑point dip from the prior year—demonstrates the effectiveness of its cost‑optimization program and supply‑chain rationalization. The company has successfully mitigated tariff impacts through manufacturing footprint adjustments, and the remaining 400 million in 2026 tariff exposure is expected to be absorbed through these efficiencies. This margin resilience provides a cushion for pricing pressure while still supporting the company’s aggressive growth plans.
  • The medical‑surgery (MedSurg) segment, which grew 19.1% U.S. sales, continues to be the fastest‑growing med‑tech segment, powered by a high‑margin product mix and strategic sales‑force specialization. The launch of high‑penetration products such as SteraShield and Neptune, coupled with new acquisitions like Inari, expands the portfolio’s breadth and provides a platform for future cross‑sell opportunities. This diversification ensures that the company is not overly reliant on any single product line, reducing volatility in revenue streams.
Read more

Bear case

  • The company’s 2026 tariff impact of approximately 400 million, double the hit in 2025, remains a material cost risk that could erode margins if mitigation strategies fail to materialize. While Stryker has offset a portion of the tariff exposure through supply‑chain realignment, the remaining burden could pressure operating margin growth and dilute the projected 30.2% adjusted operating margin. Given the sensitivity of the medical‑device industry to trade policy, any escalation in tariffs or new trade restrictions could further compress profitability.
  • Competitive headwinds in the vascular ischemic segment, highlighted by a 4.3% U.S. organic growth offset by intense price and volume pressure, signal potential erosion of market share in a high‑margin, high‑growth area. The company’s launch of the BroadWay catheter, though well received, remains early in its lifecycle, and the broader competitive landscape—including established players with entrenched reimbursement networks—could limit Stryker’s ability to capture additional volume. Overreliance on a single high‑margin segment may expose the company to concentration risk.
  • Europe’s “slower capital environment” and the regulatory uncertainty associated with the EU MDR framework pose significant challenges to the company’s growth trajectory outside the United States. Delays in product approvals, as experienced with Insignia and Pangaea, could postpone revenue recognition and create a gap in the international order book. A prolonged slowdown in the European market would also strain the company’s ability to diversify revenue streams and could shift pressure onto the U.S. business, where growth is already maturing.
  • The company’s heavy reliance on capital‑equipment sales—constituting roughly 25% of total revenue—exposes it to cyclical swings in hospital capital budgets. A tightening of payer reimbursement or a slowdown in hospital expansion initiatives could reduce the demand for Stryker’s orthopedics and neurotechnology implants. Given that capital equipment decisions are often long‑term and capital‑intensive, any macro‑economic slowdown could have a delayed but pronounced effect on the company’s top‑line.
  • The projected incremental $200 million tariff impact in the first half of 2026, coupled with the company’s plan to issue additional debt, may strain cash flow and increase interest expense, thereby reducing net earnings. The increase in “other income and expense” noted in the Q4 results—$107 million versus $56 million in 2024—highlights a growing interest cost burden that could limit Stryker’s ability to fund further growth or return capital to shareholders through dividends or share buybacks.
Read more

Consolidation Items Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 166.51 Bn 25.64 3.76 12.93 Bn
2 SYK Stryker Corp 129.03 Bn 39.76 5.14 15.86 Bn
3 MDT Medtronic plc 109.80 Bn 23.79 3.09 28.07 Bn
4 BSX Boston Scientific Corp 93.90 Bn 32.20 4.68 11.44 Bn
5 EW Edwards Lifesciences Corp 46.23 Bn 43.43 7.62 0.60 Bn
6 PHG Koninklijke Philips Nv 31.71 Bn 26.97 1.57 9.41 Bn
7 DXCM Dexcom Inc 23.91 Bn 28.50 5.13 -
8 STE STERIS plc 21.55 Bn 30.23 3.70 1.90 Bn